Price Change to Note: What’s in Cara Therapeutics Inc After Today’s Huge Increase?

Price Change to Note: What's in Cara Therapeutics Inc After Today's Huge Increase?

The stock of Cara Therapeutics Inc (NASDAQ:CARA) is a huge mover today! About 805,477 shares traded hands. Cara Therapeutics Inc (NASDAQ:CARA) has risen 37.83% since April 21, 2016 and is uptrending. It has outperformed by 32.50% the S&P500.
The move comes after 8 months positive chart setup for the $244.40 million company. It was reported on Nov, 23 by Barchart.com. We have $11.04 PT which if reached, will make NASDAQ:CARA worth $17.11M more.

Analysts await Cara Therapeutics Inc (NASDAQ:CARA) to report earnings on March, 9. They expect $-0.51 EPS, down 45.71% or $0.16 from last year’s $-0.35 per share. After $-0.42 actual EPS reported by Cara Therapeutics Inc for the previous quarter, Wall Street now forecasts 21.43% negative EPS growth.

Cara Therapeutics Inc (NASDAQ:CARA) Ratings Coverage

Out of 5 analysts covering Cara Therapeutics (NASDAQ:CARA), 5 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. Cara Therapeutics has been the topic of 6 analyst reports since July 27, 2015 according to StockzIntelligence Inc. The firm earned “Buy” rating on Thursday, October 13 by H.C. Wainwright. Cantor Fitzgerald initiated the shares of CARA in a report on Wednesday, November 4 with “Buy” rating. Needham maintained the shares of CARA in a report on Friday, July 24 with “Buy” rating.

According to Zacks Investment Research, “Cara Therapeutics, Inc. is a biopharmaceutical company. The company is focused on developing and commercializing new chemical entities designed to alleviate pain. Cara Therapeutics, Inc. is based in Shelton, United States.”

Insitutional Activity: The institutional sentiment increased to 1.83 in Q2 2016. Its up 1.13, from 0.7 in 2016Q1. The ratio is positive, as 27 funds sold all Cara Therapeutics Inc shares owned while 20 reduced positions. 6 funds bought stakes while 27 increased positions. They now own 13.15 million shares or 19.13% less from 16.26 million shares in 2016Q1.
Millennium Management Ltd Limited Liability Company reported 441,620 shares or 0% of all its holdings. Bogle Mngmt L P De accumulated 0.04% or 133,545 shares. Jacobs Levy Equity Management holds 13,100 shares or 0% of its portfolio. Legal General Group Public Limited Liability Company has 0% invested in the company for 3,710 shares. Blackrock Invest Ltd Liability Company last reported 83,757 shares in the company. California State Teachers Retirement Sys has 44,054 shares for 0% of their US portfolio. The Germany-based Deutsche Comml Bank Ag has invested 0% in Cara Therapeutics Inc (NASDAQ:CARA). Geode Capital Limited Co owns 119,201 shares or 0% of their US portfolio. Citigroup Inc holds 1,862 shares or 0% of its portfolio. Nationwide Fund Advsrs owns 20,187 shares or 0% of their US portfolio. State Street has 0% invested in the company for 321,834 shares. Wells Fargo And Mn holds 0% or 5,285 shares in its portfolio. Jpmorgan Chase accumulated 0% or 424,872 shares. Rho Prtnrs reported 3.07 million shares or 11.8% of all its holdings. Blackrock Institutional Com Na accumulated 416,785 shares or 0% of the stock.

CARA Company Profile

Cara Therapeutics, Inc., incorporated on July 2, 2004, is a clinical-stage biopharmaceutical company. The Firm is focused on developing and commercializing chemical entities designed to alleviate pain and pruritus by focusing on kappa opioid receptors. The Firm operates through the activities related to the discovery and development of novel therapeutics to treat serious medical conditions, including pain and pruritus segment. The Firm is engaged in developing product candidates that focus on the body’s peripheral nervous system. The Company’s product candidate pipeline includes I.V. CR845 for acute pain; I.V. CR845 for uremic pruritus; Oral CR845 for acute and chronic pain, and CR701 for neuropathic and inflammatory pain.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Related posts

Leave a Comment